MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex

Journal of Neuroimaging

Volumn 13, Issue 3, 2003, Pages 234-239

  Parry, A ^a   Clare, S ^a   Jenkinson, M ^a   Smith, S ^a   Palace, J ^b   Matthews, P M ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Echo planar imaging; MRI; Multiple sclerosis; Pathology; T1 relaxometry

Indexed keywords

GLATIRAMER; IMMUNOMODULATING AGENT; STEROID;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HISTOGRAM; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAXATION TIME; SENSITIVITY AND SPECIFICITY; TECHNIQUE; TIME; TREATMENT INDICATION; TREATMENT OUTCOME; WHITE MATTER;

ADULT; ANALYSIS OF VARIANCE; BRAIN; CEREBRAL CORTEX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0037783991     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403013003006     Document Type: Article

References (26)

1. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50(5):1282-1288.
2. van Waesberghe JH, Kamphorst W, de Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46(5):747-754.
3. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45(9):1684-1690.
4. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47(6):1469-1476.
5. Sailer M, Losseff NA, Wang L, Gawne-Cain M, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow up study. Eur J Neurol 2001;8(1):37-42.
6. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000;55(2):185-192.
7. Gasperini C, Pozzilli C, Bastianello S, et al. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images. J Neurol Neurosurg Psychiatry 1999;67(5):579-584.
8. Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J Neurol 2003;250(2):171-178.
9. , Clare S, Jezzard P. Rapid T(1) mapping using multislice echo planar imaging. Magn Reson Med 2001;45(4):630-634.
10. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121(1):103-113.
11. Griffin CM, Parker GJ, Barker GJ, Thompson AJ, Miller DH. MTR and T1 provide complementary information in MS NAWM, but not in lesions. Mult Scler 2000;6(5):327-331.
12. Ropele S, Strasser-Fuchs S, Augustin M, et al. A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis. Am J Neuroradiol 2000;21(10):1885-1891.
13. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 2002;58(8): 1147-1153.
14. Poser CM. Diagnostic criteria for multiple sclerosis: an addendum. Ann Neurol 1987;22(6):773.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-1452.
16. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001;20(1):45-57.
17. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5(2):143-156.
18. Qian ZM, Shen X. Brain iron transport and neurodegeneration. Trends Mol Med 2001;7(3):103-108.
19. Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001;185(1): 19-26.
20. Drayer B, Burger P, Hurwitz B, Dawson D, Cain J. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? Am J Roentgenol 1987;149(2):357-363.
21. Grimaud J, Millar J, Thorpe JW, Moseley IF, McDonald WI, Miller DH. Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59(3): 306-308.
22. Bakshi R, Shaikh ZA, Janardhan V. MRI T2 shortening ("black T2") in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000;11(1):15-21.
23. Barnes D, McDonald WI, Johnson G, Tofts PS, Landon DN. Quantitative nuclear magnetic resonance imaging: characterisation of experimental cerebral oedema. J Neurol Neurosurg Psychiatry 1987;50(2):125-133.
24. Barnes D, McDonald WI, Landon DN, Johnson G. The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. Brain 1988;111(1):83-94.
25. Griffin CM, Chard DT, Parker GJ, Barker GJ, Thompson AJ, Miller DH. The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing-remitting multiple sclerosis. J Neurol 2002;249(2):193-199.
26. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119(6):2009-2019.